Skip to main content
. Author manuscript; available in PMC: 2009 Mar 5.
Published in final edited form as: Cell. 2008 Aug 7;134(5):877–886. doi: 10.1016/j.cell.2008.07.041

Figure 2. Patient-derived iPS lines exhibit markers of pluripotency.

Figure 2

Figure 2

Figure 2

ADA-iPS2, GD-iPS1, DMD-iPS1, BMD-iPS1, DS1-iPS4, DS2-iPS10, PD-iPS1, JDM-iPS1, SBDS-iPS1, HD-iPS4, LNSc-iPS2, JDM-iPS2 were established from a fibroblast or mesenchymal cells (Table 1). Disease specific iPS cell lines maintain a morphology similar to hES cells when grown in co-culture with mouse embryonic feeder fibroblasts (MEFs). Patient-specific iPS cells express alkaline phosphatase (AP). Also, as shown here via immunohistochemistry, patient-specific cells express pluripotency markers including Tra-1-81, NANOG, OCT4, Tra-1-60, SSEA3 and SSEA4. 4,6-Diamidino-2-phenylindole (DAPI) staining is shown at right and indicates the total cell content per image.